Viz.ai Collaborates with Addario Lung Cancer Medical Institute (ALCMI) to Integrate AI into Lung Cancer Detection
Shots:
- Viz.ai has collaborated with the Addario Lung Cancer Medical Institute (ALCMI), an association of 25 lung cancer research institutions, to improve early lung cancer detection & clinical workflows for nodule evaluation to make precise decisions using AI
- The partnership will combine ALCMI’s patient engagement & research expertise with Viz.ai’s AI-based care coordination across 1,700 hospitals for the same
- The collaboration further seeks to reduce healthcare disparities in rural and community areas by training local physicians with advanced treatments & methodologies
Ref: Viz.ai | Image: Viz.ai & Addario Lung Cancer
Related Post:- The NMPA Approves Simcere Zaiming’s Enlituo (Biosimilar, Cetuximab Beta) as a 1L Treatment for Metastatic Colorectal Cancer (mCRC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
